Top 50 Ai For Genomics

Genomenon develops the Mastermind Genomic Intelligence Platform, which utilizes AI to analyze and interpret extensive genomic datasets, providing actionable insights for clinical diagnostics and precision therapeutics. The platform enhances variant interpretation efficiency, enabling healthcare professionals to make informed decisions based on a comprehensive database of over 26 million curated genomic variants.

GENOBOTICS AI provides a cloud‑native platform that applies deep‑learning models to automatically annotate genomic variants and predict their therapeutic relevance. Users upload standard formats (VCF, BAM, FASTQ) and receive batch‑processed results within minutes via RESTful APIs or an interactive dashboard, with end‑to‑end encryption and HIPAA/GDPR compliance for pharmaceutical, biotech, and academic precision‑medicine teams.

Emedgene utilizes AI algorithms to analyze genomic data for diagnostics and discovery, enabling healthcare providers to identify genetic conditions more efficiently. The platform enhances the accuracy of genomic interpretations, reducing the time and cost associated with traditional diagnostic methods.

Enigma Genomics utilizes next-generation sequencing technologies and artificial intelligence to decode individual genomes, providing personalized genetic insights that inform health decisions. The platform enables users to access and control their genetic data for life, facilitating proactive disease prevention and tailored medical treatments.

Deep Genomics utilizes a proprietary AI platform to analyze complex RNA biology data, identifying novel therapeutic targets for genetic conditions. By streamlining the drug discovery process, the company aims to develop RNA therapies that can precisely target genetic causes, significantly reducing the time and cost associated with traditional methods.

Imagene AI develops an AI-based genomic testing solution that utilizes histological data from cancer biopsies to inform personalized treatment strategies. This technology enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies for patients.

SeqOne provides a clinical decision support platform that utilizes AI-driven bioinformatics to analyze next-generation sequencing (NGS) data for germline and somatic variants. The platform enhances diagnostic accuracy and efficiency by identifying complex genomic events that standard pipelines often overlook, thereby improving patient outcomes in precision medicine.

GenBio AI develops the AI-Driven Digital Organism (AIDO), a unified system of multiscale foundation models for predicting, simulating, and programming biology. AIDO integrates diverse biological data from DNA to single-cell information, enabling holistic understanding and accelerating breakthroughs in drug discovery and bio-engineering.

Genomate Health develops a computational platform that utilizes artificial intelligence to analyze the unique molecular profiles of cancer patients' tumors, enabling oncologists to identify the most effective targeted therapies. This approach improves treatment outcomes by providing data-backed recommendations that consider multiple genetic alterations, significantly increasing the likelihood of positive patient responses.

MEDHINI is a generative AI-powered software platform that provides genomics-based multimodal solutions for healthcare diagnostics, focusing on areas such as antimicrobial resistance and virtual clinical trials. The platform enhances diagnostic accuracy and accessibility in pulmonology, neurology, nephrology, cardiology, and oncology, addressing the need for affordable healthcare solutions with measurable social impact.

Cassidy Bio offers an AI‑driven platform that predicts the efficacy, safety, off‑target risk, and repair outcomes of genome‑editing guides, enzymes, and delivery methods using a model trained on 70 k diverse human genomes and proprietary high‑throughput assay data. The system ranks candidates in silico and provides a cloud‑hosted dashboard and RESTful API for biotech and pharmaceutical teams to shortlist therapeutic designs in weeks, with continuous model improvement from experimental validation.

BostonGene utilizes an AI-powered multi-omics platform to perform molecular and immune profiling, enabling precise therapy matching for patients with cancer and immune-related diseases. This approach identifies actionable mutations and biomarkers, generating personalized treatment roadmaps that enhance clinical decision-making and improve patient outcomes.

Neurolov offers a cloud‑native platform that runs curated machine‑learning models on genomics, transcriptomics, proteomics and phenotypic data to produce predictive biomarkers, pathway activity scores, and compound efficacy forecasts. The service automates data ingestion, preprocessing, feature engineering and model inference, delivering results through interactive dashboards and API endpoints for integration with LIMS and downstream analysis. By providing a managed, scalable compute environment with versioned model registries and GxP/HIPAA compliance, it shortens the turnaround time for drug discovery teams.

Ingenix provides a multimodal generative AI platform that builds digital twins of drug candidates by integrating genomics, proteomics, imaging, literature, and electronic health records across molecular to population scales. The system delivers detailed, interpretable predictions of clinical efficacy, safety endpoints, and adverse events, and supports natural‑language “what‑if” queries for trial design and candidate prioritization. It is aimed at pre‑clinical, strategic R&D, and clinical development teams in pharmaceutical and biotechnology companies.

The startup employs AI algorithms to analyze genetic data for identifying mutations associated with hereditary diseases. This technology enables healthcare providers to deliver accurate diagnoses and tailored treatment plans for patients with genetic disorders.

Healx provides an AI‑powered platform that integrates genomics, phenotypic and clinical data to identify and prioritize repurposed or optimized compounds for rare disease indications. The system automates in silico screening, predictive efficacy and safety modeling, and workflow orchestration to move candidates from computational prediction to preclinical validation, lowering discovery costs and timelines. It is offered to pharmaceutical, biotech and research consortium partners seeking to expand rare‑disease pipelines.

The startup develops gene therapies using artificial intelligence to enhance the design and optimization of genetic constructs. Their technology enables researchers to create more predictable and controllable gene therapies, facilitating faster development for various applications.

Rayca Precision utilizes AI-driven bioinformatics platforms, OncoCrest™ and RSA2™, to analyze genomic and transcriptomic data for personalized cancer treatment strategies. The technology addresses the challenge of cancer heterogeneity by providing precise predictions of drug responses and patient outcomes, enabling tailored therapeutic interventions.

WhiteLab Genomics utilizes a proprietary platform that combines graph knowledge technology and machine learning to optimize the design of payloads and vectors for gene and cell therapies. This technology accelerates the development process, reducing costs and time to market for genomic medicines, making them more accessible to patients.

Verge Genomics utilizes a proprietary all-in-human, AI-powered drug discovery platform that integrates machine learning with a large multi-omics database derived from human tissue. The company focuses on developing effective treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis, by rapidly translating insights from human biology into drug candidates.

Curenetics utilizes an AI-powered platform that integrates genomics, imaging, and clinical data to predict individual patient responses to cancer therapies. This technology addresses the high variability in treatment effectiveness, enabling personalized treatment plans that improve patient outcomes and reduce unnecessary healthcare costs.

The startup has developed an artificial intelligence platform for biomarker discovery and sequencing analysis, focusing on extracting biosignatures from single-cell and multi-omics data. This platform enables physicians to efficiently analyze complex disease patterns, reducing data processing time and costs while enhancing insights for patient stratification.

Genialis offers AI-driven platforms that translate RNA‑sequencing data into clinically validated oncology biomarkers for drug development. Its Supermodel, trained on a large transcriptomic repository, produces explainable predictive classifiers—such as krasID, Expressions, and ResponderID—for patient stratification, response forecasting, and mechanistic insight, delivered through secure cloud services and APIs.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

The startup has developed a digital diagnostics platform that utilizes artificial intelligence for genetic analysis and clinical decision support, enhancing the traceability and interoperability of bioinformatics data. This technology enables researchers and clinicians to efficiently access and reuse critical information, thereby expediting the diagnosis process for various diseases.

The startup develops a bioinformatics platform that employs artificial intelligence to analyze fetal cell-free DNA extracted from maternal blood samples during the first trimester. This technology enables early detection of genetic disorders, including point mutations and chromosomal anomalies, in a non-invasive and cost-effective manner.

OMGene uses AI to analyze genetic data, providing personalized recommendations for career development, mental well-being, and healthy aging. The platform delivers actionable insights based on individual genetic predispositions.

Ensocell utilizes single-cell genomics, AI-driven computational tools, and advanced cell models to identify intervention points for autoimmune, inflammatory, and fibrotic diseases. The company focuses on discovering novel therapeutics to improve treatment outcomes in these challenging health conditions.

Metagenomi utilizes metagenomics and machine learning to discover and develop novel genome editing systems that enable precise modifications to the human genome. This technology addresses the limitations of existing gene editing methods by providing a versatile toolbox capable of targeting specific sites for therapeutic interventions.

Akkure is a digital platform utilizing AI and genomics to enhance clinical trial recruitment for oncology by providing precise patient-trial matching and personalized trial recommendations. The platform ensures GDPR and HIPAA compliance, facilitating secure access and ownership of clinical data while streamlining the enrollment process for patients and healthcare providers.

Ophiomics develops in vitro diagnostic devices that utilize artificial intelligence and genomics to enhance early cancer detection and optimize treatment selection. Their technology integrates machine learning algorithms with clinical and biomarker data to improve decision-making for clinicians, ultimately aiming to enhance patient outcomes in oncology.

Provides an AI-powered platform for analyzing complex medical data, including transcriptomics, epigenomics, and proteomics, using modular machine learning techniques. This system accelerates research by delivering fast, high-quality insights for identifying therapeutic targets, biomarkers, and disease mechanisms, reducing time and cost compared to traditional methods.

Accelerates precision medicine by leveraging advanced genomic analysis and machine learning to tailor treatments based on individual genetic profiles. This approach addresses the limitations of one-size-fits-all therapies, enabling more effective and personalized healthcare solutions.

This startup provides AI-powered software that accelerates biomedical discovery by automating data generation, analysis, and hypothesis testing. Their platform helps biotech and pharmaceutical scientists quickly derive insights from genomic data, significantly reducing the time and cost associated with traditional research methods.

My Genome Screen provides an AI-powered platform that accelerates rare disease diagnosis by efficiently interpreting genetic variants. Its system prioritizes disease-causing mutations from complex genomic data, enabling clinicians to identify genetic disorders faster and facilitate targeted treatments.

The startup develops AI-powered precision medicine technology that utilizes multi-omics analysis to decode cellular health and identify molecular causes of diseases. This approach enhances early disease detection and enables targeted therapies for non-invasive prenatal and oncology testing.

Algen Biotechnologies utilizes a proprietary CRISPR gene-modulation system and advanced AI models to decode complex gene networks and identify disease-driving RNA signaling pathways. This approach accelerates therapeutic drug discovery by providing high-confidence insights into the biological mechanisms underlying various diseases.

Sun Genomics utilizes AI and whole-genome sequencing to analyze individual gut microbiomes, creating personalized probiotic formulations tailored to specific health goals. This approach addresses digestive issues, food tolerance, and overall gut health by providing custom solutions based on unique microbial profiles.

The startup operates a genomics analytics platform that provides clinical genome reporting and AI-driven insights for monogenic and polygenic risk assessment, pharmacogenomics, and wellness traits. This technology enables healthcare providers to make informed decisions based on precise genomic data, enhancing patient care and research capabilities.

This company offers a clinical-grade DNA test that uses AI and machine learning to identify genetic risks for diseases like cancer and heart disease. The test provides actionable health insights, enabling early detection and better-informed healthcare decisions.

Uses AI-powered algorithms to analyze electronic health records and genomic data, rapidly matching cancer patients to suitable clinical trials in minutes. This platform streamlines the trial recruitment process by integrating with EHR systems and genomic databases, reducing the time and cost associated with manual matching. By providing precise, personalized trial recommendations, it expands treatment options and accelerates medical research globally.

Genz develops AI algorithms for genomic data analysis to facilitate personalized treatment plans for women with breast cancer. By leveraging advanced data analytics, the company aims to enhance the precision of therapeutic interventions tailored to individual genetic profiles.

DNAstack offers Omics AI, a software suite that enables the secure connection, protection, and analysis of federated omics and health data using AI-powered tools compliant with Global Alliance for Genomics & Health standards. This platform addresses the challenge of accessing and analyzing large, sensitive datasets without the need to move them, facilitating collaborative research across distributed networks.

Genomii utilizes AI-driven analysis of genetic, lifestyle, and biometric data to deliver personalized wellness insights and recommendations. The platform addresses the challenge of optimizing individual health and beauty by providing real-time guidance tailored to users' unique genetic profiles and daily habits.

This startup offers a clinical genome interpretation platform that uses AI algorithms to analyze genomic data from various sources. The platform delivers actionable genomic insights to medical professionals, enabling faster and more accurate diagnostic reports.

Deargen utilizes deep learning algorithms for genome data analysis, biomarker prediction, and drug-target interaction modeling to facilitate the discovery and optimization of new therapeutic molecules. The platform addresses the challenge of developing effective treatments for complex diseases by enabling precision medicine through targeted drug design.

This startup provides an AI-powered blockchain platform for decentralized science, specifically focused on genomics. It offers researchers access to clean, labeled, and organized genetic profiles, accelerating the development of personalized, data-driven medical solutions and reducing time-to-market for genomics-based AI applications.

IndyGeneUS AI is building the largest blockchain-encrypted repository of indigenous and diasporic African clinical and genomic data, utilizing proprietary technology to analyze multi-omics data alongside electronic health records and scientific literature. This approach enables the identification of novel biomarkers and polygenic risk scores, addressing the lack of diverse genomic data in precision medicine.

The startup operates a biomarker discovery platform that utilizes artificial intelligence and genomic analysis techniques to identify personalized cancer therapies for patients. This approach enhances patient stratification, enabling healthcare providers to deliver more effective treatment options tailored to individual needs.

enGenome offers the eVai platform, which utilizes AI and guideline-based classification to accurately interpret genomic variants for early diagnosis of rare diseases. This technology enhances clinical decision-making by providing precise genetic diagnoses, addressing the challenge of variant interpretation in translational research and routine healthcare.